Business UpdateJun 29, 2026, 08:07 AM
Alumis Highlights Positive Envudeucitinib Psoriasis Phase 3 Data
AI Summary
Alumis Inc. updated its corporate presentation for investors, highlighting significant progress in its TYK2 inhibitor pipeline. The presentation detailed positive Phase 3 results for envudeucitinib in moderate-to-severe plaque psoriasis, showing leading PASI 100 responses and robust improvements in skin clearance and quality of life. The company anticipates filing an NDA for envudeucitinib in psoriasis in Q4 2026 and expects topline data from its potentially pivotal Phase 2b SLE trial in Q3 2026. Additionally, Alumis plans to initiate a Phase 2 biomarker trial for A-005 in Parkinson's disease in 1H 2027, supported by a cash runway into Q4 2027.
Key Highlights
- Envudeucitinib Phase 3 psoriasis data showed 41.0% PASI 100 response in ONWARD1 and 39.5% in ONWARD2 at Week 24.
- Envudeucitinib Phase 3 psoriasis data showed 68.0% PASI 90 response in ONWARD1 and 62.1% in ONWARD2 at Week 24.
- Alumis expects to file an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in Q4 2026.
- Topline data from the potentially pivotal Phase 2b LUMUS trial for envudeucitinib in SLE is expected in Q3 2026.
- Initiation of a Phase 2 biomarker trial for CNS-penetrant A-005 in Parkinson’s disease is planned for 1H 2027.
- Cash, cash equivalents, and marketable securities totaled $569.5 million as of March 31, 2026.
- Alumis projects its cash runway to extend into Q4 2027.
- The total market opportunity for TYK2 molecules is projected to exceed $180 billion.
Price Impact
More from ALMS